Generic Pharmaceutical Life Science Production 
XTalks
DECEMBER 14, 2020
AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle. According to AvKARE, the error occurred at a third-party bottle filling facility.
The Pharma Data
NOVEMBER 5, 2020
and Aavis Pharmaceuticals Inc. The product will be distributed by Jubilant Cadista, a unit of Jubilant Pharma Ltd. “We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the U.S.through our marketing partner,” stated Ashok Barot , Chairman, Aavis Pharmaceuticals. YARDLEY, Pa.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
JUNE 8, 2022
Biosimilars are generic versions of biologics medicines that already have regulatory approval (called the reference product) and have expired patents leading to a loss of exclusivity rights. Related: Cyltezo Becomes First FDA-Approved Interchangeable Humira Biosimilar.
XTalks
DECEMBER 14, 2020
AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle. According to AvKARE, the error occurred at a third-party bottle filling facility.
Pharma in Brief
DECEMBER 3, 2023
The Regulations became a moving target for the innovative and generic pharmaceutical industries, being amended seven times between 1998 and 2016. These provisions were further amended in 2015 to clarify the level of product specificity required for combination drugs and formulations. Frequent amendments (1998–2016).
Pharmaceutical Technology
DECEMBER 22, 2022
This consists of any projects that have expanded the company’s footprint in the sector, including: contract wins; launching in new territories; launching new product lines; the acquisition and expansion of facilities and real estate; acquisition of new machinery or other assets; improved logistics; partnerships; and significant staff increases.
The Pharma Data
MAY 15, 2023
Feinglass, MD, MPH was most recently Chief Medical Officer for Life Sciences and Diagnostics and Vice President Global Medical Affairs and Policy, Life Sciences and Diagnostics, at Danaher, a global science and technology company. Urs will be Chair of the Human Capital & ESG Committee of Sandoz. Dr. Shamiram R.
Expert insights. Personalized for you.
98 
Let's personalize your content